Login
$CGTX
$0.65 +$0.01 (1.75%) After hours

$CGTX SEC Filings

Filed On Filing
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition; Notice of Delisting or Failure to Satisfy a Listing Rule

Purchase, NY – November 5, 2026 – Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results...

22 Oct 2026 8-K: Other Events

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies

07 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

Purchase, NY – August 6, 2026 – Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results f...

24 Jun 2026 8-K: Other Events

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes

22 Jun 2026 Form 4: Khattar Jack A., Director

Received 25,000 shares as a grant or award

22 Jun 2026 Form 4: Monia Brett P, Director

Received 25,000 shares as a grant or award

22 Jun 2026 Form 4: Wallace Peggy, Director

Received 25,000 shares as a grant or award

22 Jun 2026 Form 4: Richstone Ellen B, Director

Received 25,000 shares as a grant or award

22 Jun 2026 Form 4: Fletcher Aaron G.l., Director and 9 others

Received 25,000 shares as a grant or award

18 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 17, 2026, Cognition Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The Annual Meeting was conducted virtually, and the following is a brief description of the final voting resul...

04 Jun 2026 8-K: Regulation FD Disclosure

https://cogrx.com COGNITION THERAPEUTICS · NASDAQ: CGTX An Investigational Oral Therapy Advancing Toward Registrational Development June 2026 · Jefferies Global Healthcare Conference Zervimesine in DLB Psychosis

21 May 2026 8-K: Other Events

- Positive Discussion on Path Forward for Registrational Program -

08 May 2026 10-Q
07 May 2026 8-K: Results of Operations and Financial Condition

Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to inform registrational plans for zervimesine in DLB psychosis

04 May 2026 Form 4: Doyle John Brendan, Chief Financial Officer

Gave up 8,567 shares to cover exercise price or tax ($11K)

27 Apr 2026 ARS
27 Apr 2026 DEFA14A
27 Apr 2026 Proxy statement: annual meeting on June 17, 2026

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support